What's Going On With BioMarin Stock On Tuesday?

Impact · against what's priced in

BioMarin's acquisition of Amicus Therapeutics provides immediate revenue diversification and EPS accretion, potentially offsetting competitive pressures on its Voxzogo drug. Amicus shareholders benefit from a definitive $4.8 billion equity valuation.

FOLD+0.60

No priced-in read yet

In context

The company is being acquired by BioMarin for a total equity value of approximately $4.8 billion.

Read from the article alone

Actual

• m and a
• revenue growth
• healthcare
• biotech
• pharmaceuticals
• BMRN
• FOLD
• acquisition
• rare disease

Search tags